MetaVia

MTVA · Nasdaq · United States

Share price · MTVA

$1.06-0.43 (-28.86%) 3M

close as of 2026-11-18 · 24h delayed · vol 95K (0.6x 30-day avg)

Loading chart…

Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento

Compare with peers →

Unusual price moves

Days when MTVA's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked

  1. 18 Nov 2026-15.2%
  2. 6 Nov 2026+31.2%
  3. 5 Nov 2026-18.7%
  4. 27 Oct 2026-5.3%
  5. 26 Oct 2026-12.0%
  6. 8 Oct 2026-8.2%
  7. 18 Sep 2026+8.8%

    Nothing announced by MTVA that day or the session before.

  8. 22 May 2026+34.1%
  9. 20 May 2026+53.7%
  10. 19 May 2026+69.4%

Share of unusual movement by asset

For each asset, the share of MTVA's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.

AssetEvent daysShare of unusual movement
DA-1726
events and moves
2313%
Vanoglipel
events and moves
111%
Other company news (earnings, financing, releases naming no asset)—21%
Sessions with no dated event—64%

Assets

(2 total)
2Total Assets
0Approved
0Phase 3 / Filed
2Phase 1–2 / Early
3Diseases
Quick filter:
Showing 2 of 2 assets
Target & Modality
Phase 2
GPR119Small molecule
Type 2 DiabetesMASH / NASH
Phase 1
GLP-1/glucagon receptor (dual)Peptide
Obesity

Upcoming events

No upcoming trial completions or earnings dates on record for this company's assets.

Financial reports

Quarterly & interim (16)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q3—$2.6M$8.8M$4.6M-$3.7M operating cash flowreport ↗
View 15 more
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q2——$13M$5.3M-$3.8M operating cash flowreport ↗
2026-Q1——$14M$3.8M-$4.3M operating cash flowreport ↗
2025-Q3——$14M$3.4M-$3.0M operating cash flowreport ↗
2025-Q2——$18M$4.0M-$3.1M operating cash flowreport ↗
2025-Q1—$2.3M$11M$3.7M-$4.8M operating cash flowreport ↗
2024-Q3—$4.5M$22M$5.7M-$5.6M operating cash flowreport ↗
2024-Q2—$8.1M$28M$10M-$7.3M operating cash flowreport ↗
2024-Q1—$4.9M$16M$6.7M-$6.4M operating cash flowreport ↗
2023-Q3—$2.3M$26M$3.8M-$2.8M operating cash flowreport ↗
2023-Q2—$2.4M$29M$0.7M-$2.0M operating cash flowreport ↗
2023-Q1—$0.6M$31M$2.6M-$2.5M operating cash flowreport ↗
2022-Q3—$0.6M$6.4M$3.1M-$2.4M operating cash flowreport ↗
2022-Q2—$1.0M$8.8M$3.3M-$2.7M operating cash flowreport ↗
2022-Q1—$0.9M$12M$2.9M-$4.8M operating cash flowreport ↗
2021-Q3—$1.4M$7.0M$3.5M-$2.5M operating cash flowreport ↗

Annual history (5 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY——$10M$3.2M-$16M operating cash flowreport ↗

MetaVia reported a net loss of $13.0 million for the full year 2025, compared with a net loss of $27.6 million in 2024. R&D expenses were approximately $6.8 million, down approximately $14.8 million YoY, while cash and cash equivalents totaled $10.3 million as of December 31, 2025, versus $16.0 million at year-end 2024. Revenue was not disclosed.

MetaVia guided that its existing cash, together with gross proceeds of approximately $9.3 million from a January 2026 public offering, is expected to fund operations into the fourth quarter of 2026. Positive Phase 1 data for DA-1726 showed 9.1% weight loss with improved glucose control and liver benefit, and the company plans to initiate Phase 1 Part 3 titration studies in April 2026 with data expected in the fourth quarter. It also presented positive Phase 2a data for vanoglipel (DA-1241) in MASH at AASLD and is working to schedule an end-of-Phase 2 meeting with the FDA.

View 4 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY—$22M$16M$6.9M-$25M operating cash flowreport ↗
2023-FY—$9.2M$22M$3.1M-$11M operating cash flowreport ↗
2022-FY—$2.8M$33M$3.5M-$12M operating cash flowreport ↗
2021-FY—$6.5M$16M$3.8M-$15M operating cash flowreport ↗

Insider transactions

Open-market activity, trailing 12 months: 0 purchases (—), 0 sales (—). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.

Source
2026-10-12Browne Sarah Kaplan · Chief Medical OfficerAward / grant53,000——Form 4
2026-06-08Glickman Mark A · directorAward / grant17,186——Form 4
2026-06-08KOVEN ANDREW I · directorAward / grant17,186——Form 4
2026-06-08GROVES JASON L · directorAward / grant17,186——Form 4
2026-06-08Salsbury Michael · directorAward / grant17,186——Form 4
2026-06-08STRICKLAND D GORDON · directorAward / grant17,186——Form 4
2026-06-08Tursi James Patrick · directorAward / grant17,186——Form 4
2026-01-23Kim Hyung Heon · director, CEO & PresidentAward / grant32,000——Form 4

Institutional holders

From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 12 reporting institutions held 0.1M shares ($80K, 1.0% of shares outstanding).

#InstitutionSharesValue
1GEODE CAPITAL MANAGEMENT, LLC33,635$40K
2JANE STREET GROUP, LLC10,903$13K
3Aries Wealth Management10,000$12K
4VANGUARD FIDUCIARY TRUST CO6,940$8K
5Tower Research Capital LLC (TRC)2,602$3K
6VANGUARD CAPITAL MANAGEMENT LLC2,222$3K
7BlackRock, Inc.479$575
8SBI Securities Co., Ltd.205$246
9Caitong International Asset Management Co., Ltd3$4
10BROWN BROTHERS HARRIMAN & CO2$2
11DANSKE BANK A/S2$2
12UBS Group AG1$1